标题/作者	年份
Oral and injectable (non-insulin) pharmacological agents for type 2 diabetes KR Feingold, B Anawalt, A Boyce, G Chrousos, K Dungan, A Grossman, ... Endotext. South Dartmouth (MA)	2020
SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects A Tentolouris, P Vlachakis, E Tzeravini, I Eleftheriadou, N Tentolouris International journal of environmental research and public health 16 (16), 2965	2019
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus AJ Scheen Nature reviews endocrinology 16 (10), 556-577	2020
An update on the safety of SGLT2 inhibitors AJ Scheen Expert opinion on drug safety 18 (4), 295-311	2019
Sodium–glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study CV Dave, S Schneeweiss, D Kim, M Fralick, A Tong, E Patorno Annals of internal medicine 171 (4), 248-256	2019
Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population‐based study of older women and men with diabetes IC Lega, SE Bronskill, MA Campitelli, J Guan, NM Stall, K Lam, ... Diabetes, Obesity and Metabolism 21 (11), 2394-2404	2019
Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis J Menne, E Dumann, H Haller, BMW Schmidt PLoS medicine 16 (12), e1002983	2019
Pharmacological treatment of hyperglycemia in type 2 diabetes SI Taylor, ZS Yazdi, AL Beitelshees The Journal of Clinical Investigation 131 (2)	2021
Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes—systematic review and meta-analysis of randomized placebo-controlled trials HM Salah, SJ Al'Aref, MS Khan, M Al-Hawwas, S Vallurupalli, JL Mehta, ... American heart journal 232, 10-22	2021
The role of diosgenin in diabetes and diabetic complications Q Gan, J Wang, J Hu, G Lou, H Xiong, C Peng, S Zheng, Q Huang The Journal of steroid biochemistry and molecular biology 198, 105575	2020
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks SI Taylor, JE Blau, KI Rother, AL Beitelshees The Lancet Diabetes & Endocrinology 7 (12), 949-958	2019
Post-transplantation diabetes in kidney transplant recipients: an update on management and prevention C Conte, A Secchi Acta Diabetologica 55, 763-779	2018
Therapy of type 2 diabetes R Landgraf, J Aberle, AL Birkenfeld, B Gallwitz, M Kellerer, H Klein, ... Experimental and Clinical Endocrinology & Diabetes 127 (S 01), S73-S92	2019
Erectile dysfunction and diabetes: A melting pot of circumstances and treatments G Defeudis, R Mazzilli, M Tenuta, G Rossini, V Zamponi, S Olana, ... Diabetes/metabolism research and reviews 38 (2), e3494	2022
Therapie des Typ-2-Diabetes R Landgraf, J Aberle, AL Birkenfeld, B Gallwitz, M Kellerer, H Klein, ... Diabetologie und Stoffwechsel 14 (S 02), S167-S187	2019
Sodium–glucose cotransporter 2 inhibitors: A case study in translational research AL Beitelshees, BR Leslie, SI Taylor Diabetes 68 (6), 1109-1120	2019
Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews R Pelletier, K Ng, W Alkabbani, Y Labib, N Mourad, JM Gamble Therapeutic Advances in Drug Safety 12, 2042098621989134	2021
Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations K Yau, A Dharia, I Alrowiyti, DZI Cherney Kidney international reports 7 (7), 1463-1476	2022
Sodium glucose co-transporter 2 inhibitors and heart failure RK Ghosh, GC Ghosh, M Gupta, D Bandyopadhyay, T Akhtar, ... The American Journal of Cardiology 124 (11), 1790-1796	2019
Prevention and management of genital mycotic infections in the setting of sodium-glucose cotransporter 2 inhibitors K Engelhardt, MK Ferguson, JL Rosselli Annals of Pharmacotherapy 55 (4), 543-548	2021

1 - 20

计算机程序会自动估算并确定日期和引用次数。